Literature DB >> 1998948

Inhibition of human renal cancer by monoclonal antibody targeted methotrexate-containing liposomes in an ascites tumor model.

M Singh1, T Ghose, M Mezei, P Belitsky.   

Abstract

The monoclonal antibody DAL K29 against a human renal cell carcinoma associated cell surface antigen was covalently linked to small unilamellar lipid vesicles (SUV) containing the antifolate, methotrexate (MTX), with full retention of antibody activity. In an ascites tumor model developed after intraperitoneal inoculation of 5 x 10(6) cells of the human kidney cancer line Caki-1 per pristane primed nude mouse, the DAL K29 linked MTX-containing SUV was a more potent tumor inhibitor (P less than 0.0005) than the drug or MAB alone, MTX-containing SUV, a mixture of DAL K29 and MTX-containing SUV or MTX-containing SUV linked to an isotype matched nontumor specific IgG.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1998948     DOI: 10.1016/0304-3835(91)90082-s

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

1.  Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease.

Authors:  Jonathan Wang; Jacqueline J Masehi-Lano; Eun Ji Chung
Journal:  Biomater Sci       Date:  2017-07-25       Impact factor: 6.843

Review 2.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

3.  Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo.

Authors:  M H Vingerhoeds; P A Steerenberg; J J Hendriks; L C Dekker; Q G Van Hoesel; D J Crommelin; G Storm
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.